1
|
Shantha Kumara HMC, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, Gnjatic S, Cekic V, Old LJ, Simpson AJ, Cordon-Cardo C, Whelan RL. MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun 2012; 12:16. [PMID: 23390371 PMCID: PMC3554221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The expression of Cancer/Testis (CT) antigens in some tumors and restricted expression in normal tissue make CT antigens attractive vaccine targets. We evaluated the expression of MAGE-A3, PLAC1, GAGE, and CTAG2 in a series of colorectal cancers (CRC). CT mRNA expression was determined via quantitative PCR on paired tumors and normal tissue samples from 82 CRC patients. In addition, plasma antibody titers specific to MAGE-A3, PLAC1, GAGE, and CTAG2 were determined via ELISA. Tissue expression of MAGE-A3 was assessed via a standard IHC protocol. The Student's t-test was used for statistical analysis (significance p < 0.05). Tumor expression of MAGE-A3, CTAG2, and GAGE was compared to the levels of expression in testis. The percentage of samples that had a tumor vs. testis expression ratio above 0.1% was: MAGE-A3 (28%) and CTAG2 (17%) but no tumor presented GAGE expression levels above 0.1%. The expression levels of PLAC1 in tumors were compared to the levels in placenta, and in 12.8% of the samples analyzed, these levels were above 0.1%. Sero-reactivity specific for MAGE-A genes and PLAC1 was noted in 2.4% and 2.6% of patients, respectively. MAGE-A3 and PLAC1 may hold promise as vaccine targets for CRC. Further study is warranted.
Collapse
Affiliation(s)
- HMC Shantha Kumara
- Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
| | - Michael J. Grieco
- Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
| | - Otavia L. Caballero
- Ludwig Collaborative Laboratory for Cancer Biology and Therapy, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
| | - Tao Su
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
| | - Aqeel Ahmed
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
| | - Erika Ritter
- Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
| | - Sacha Gnjatic
- Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
| | - Vesna Cekic
- Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
| | - Lloyd J. Old
- Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
| | - Andrew J. Simpson
- Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
| | - Carlos Cordon-Cardo
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
| | - Richard L. Whelan
- Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
- Section of Colon and Rectal Surgery, Department of Surgery, New York-Presbyterian Hospital, Columbia University, New York, NY 10032, USA
| |
Collapse
|